Gyre Therapeutics (GYRE) Minority Interest (2022 - 2026)

Gyre Therapeutics (GYRE) has reported Minority Interest for 5 consecutive years, with $35.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Minority Interest fell 1.39% year-over-year to $35.7 million; the TTM figure through Mar 2026 stood at $35.7 million (down 1.39% YoY), while the FY2025 annual figure was $36.3 million, up 3.33% from the prior year.
• Minority Interest retreated to $35.7 million in Q1 2026 per GYRE's latest filing, from $36.3 million in the prior quarter.
• Across five years, Minority Interest topped out at $37.4 million in Q2 2025 and bottomed at $29.7 million in Q4 2022.
• Historically, Minority Interest has averaged $34.2 million across 5 years, with a median of $35.3 million in 2024.
• Annual changes were most pronounced in 2024 — Minority Interest climbed 17.82% — and 2026, when it declined 1.39%.
• Gyre Therapeutics' Minority Interest stood at $29.7 million in 2022, then advanced by 0.28% to $29.8 million in 2023, then climbed by 17.82% to $35.1 million in 2024, then grew by 3.33% to $36.3 million in 2025, then declined by 1.59% to $35.7 million in 2026.
• Business Quant data shows GYRE's Minority Interest at $35.7 million in Q1 2026, $36.3 million in Q4 2025, and $35.5 million in Q3 2025.